Denali Therapeutics (DNLI) Return on Invested Capital (2022 - 2023)
Denali Therapeutics' (DNLI) quarterly Return on Invested Capital came in at 0.33% in Q3 2023, up 58.0% year-on-year from 0.21% in Q3 2022, and down 18.51% on a QoQ basis from 0.28% in Q2 2023.
Denali Therapeutics (DNLI) Return on Invested Capital (2022 - 2023) Analysis & Trends
Denali Therapeutics (DNLI) has 2 years of Return on Invested Capital data on file, last reported at 0.33% in Q3 2023.
- On a quarterly basis, Return on Invested Capital rose 58.0% year-over-year to 0.33% in Q3 2023; TTM through Sep 2023 was 0.33%, a 58.0% increase from a year earlier, with the FY2025 full-year figure at 0.74%, changed N/A from the prior year.
- Return on Invested Capital for Q3 2023 stood at 0.33%, down from 0.28% in the prior quarter.
- Over the last five years, Return on Invested Capital for DNLI reached as high as 0.28% in Q2 2023 and fell as low as 1.07% in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROIC (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 0.00% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 0.04% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Denali Therapeutics | 4.37 Bn | 4.37 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | -0.33% |
| Jun 30, 2023 | -0.28% |
| Dec 31, 2022 | -0.54% |
| Sep 30, 2022 | -0.91% |
| Jun 30, 2022 | -1.07% |